Nuveen’s Abeona Therapeutics ABEO Stock Holding History

Nuveen’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$254K	Hold	56,719	–	–	﹤0.01%	3038
2025 Q4	$299K	Hold	56,719	–	–	﹤0.01%	3045
2025 Q3	$299K	Hold	56,719	–	–	﹤0.01%	3061
2025 Q2	$322K	Buy	+56,719	New	+$323K	﹤0.01%	3021
2021 Q2	–	Sell	-44,757	Closed	-$2.1M	–	3350
2021 Q1	$2.1M	Buy	44,757 +32,113	+254%	+$1.77M	﹤0.01%	2588
2020 Q4	$496K	Buy	12,644 +112	+0.9%	+$3.81K	﹤0.01%	3046
2020 Q3	$320K	Buy	12,532 +2,961	+31%	+$187K	﹤0.01%	3071
2020 Q2	$697K	Sell	9,571 -9,714	-50%	-$671K	﹤0.01%	2778
2020 Q1	$1.01M	Buy	19,285 +12,611	+189%	+$842K	﹤0.01%	2509
2019 Q4	$546K	Sell	6,674 -193	-3%	-$13.6K	﹤0.01%	2886
2019 Q3	$388K	Sell	6,867 -1,994	-23%	-$149K	﹤0.01%	3011
2019 Q2	$1.06M	Buy	+8,861	New	+$1.49M	﹤0.01%	2709

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen's ABEO Position: Q1 2026 in Review

Nuveen held its Abeona Therapeutics (ABEO) position steady in Q1 2026 at 56,719 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #3038.

Nuveen first reported a position in ABEO in Q2 2019 and has held it in 12 quarters since. The position peaked at $2.1M in Q1 2021. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

Nuveen held 56,719 shares of Abeona Therapeutics worth $254K as of Q1 2026.
Nuveen left its Abeona Therapeutics share count unchanged in Q1 2026.
Abeona Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #3038 holding.
Nuveen first reported a position in Abeona Therapeutics in Q2 2019 and has held it in 12 quarters since.
Nuveen's Abeona Therapeutics position peaked at $2.1M in Q1 2021.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.